Skip to main content
14 search results for:

Anti-GM–CSF antibodies 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-08-2021 | Temporal cell arteritis | Teaser

    New additions to the Adis Journal Club

    A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

  2. 08-02-2022 | Temporal cell arteritis | Teaser

    Rituximab and rheumatology practice in the COVID-19 era

    How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

  3. 24-05-2021 | ACR 2021 | Teaser

    ACR Convergence 2021 highlights

    3–9 November: Keep up with the latest news and interviews from the conference.

  4. 06-09-2021 | Pneumonia | Teaser

    Anifrolumab for the treatment of lupus

    Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

  5. 26-10-2020 | Vitamin D | Teaser

    Get ready for ACR Convergence 2020

    5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

  6. 06-06-2021 | EULAR 2021 | Conference coverage | Article

    Mavrilimumab shows potential for severe COVID-19

    Inhibition of GM-CSF with mavrilimumab may represent a promising treatment option for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest phase 2 study results.

  7. 10-05-2021 | Temporal cell arteritis | Teaser

    Febuxostat and cardiovascular risk in people with gout

    How will the FAST trial results impact regulatory guidance & clinical practice?

  8. 18-11-2020 | Temporal cell arteritis | Teaser

    Telemedicine in rheumatology

    Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

  9. 03-11-2020 | Osteoarthritis | News | Article

    GM-CSF inhibition may warrant further study for hand osteoarthritis

    Findings from a phase 2a proof-of-concept study suggest that the GM-CSF otilimab may deserve further investigation for inflammatory hand osteoarthritis.

  10. 10-11-2020 | ACR 2020 | Conference coverage | Article

    Reduced flare risk with mavrilimumab in giant cell arteritis

    Mavrilimumab is effective for reducing the risk for flare and maintaining sustained remission in patients with giant cell arteritis, phase 2 study findings show.

  11. 03-11-2020 | Osteoarthritis | Highlight | Teaser
    medwireNews top story

    GM-CSF inhibition may warrant further study for hand osteoarthritis

    Findings from a phase 2a proof-of-concept study suggest that the GM-CSF otilimab may deserve further investigation for inflammatory hand osteoarthritis.

  12. 22-10-2020 | Rheumatoid arthritis | News | Article

    Support for further investigation of otilimab in rheumatoid arthritis

    Otilimab, a human monoclonal antibody that inhibits GM-CSF, may warrant further investigation for the treatment of rheumatoid arthritis, indicate findings from two phase 2 trials published in The Lancet Rheumatology .

  13. 26-04-2019 | Rheumatoid arthritis | News | Article

    Namilumab shows promise in phase II trial

    They say their double-blind, placebo-controlled study “demonstrates the benefit of inhibiting macrophage activity targeting the GM-CSF for RA.”

  14. 12-04-2016 | Comorbidities | Article

    Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis

    This paper reviews the inflammatory process associated with metabolic diseases, and discusses ways anti-inflammatory agents influence these inflammatory processes and potentially impact cardiovascular disease risk. Clin Trans Immunol  2016;5,e84. doi:10.1038/cti.2016.31

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.